Xenetic Biosciences (XBIO) Net Cash Flow (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Net Cash Flow came in at -$536377.0 in Q1 2026, up 46.46% YoY from -$366218.7 in Q1 2025, and down 121.02% on a QoQ basis from -$242682.0 in Q4 2025.
Xenetic Biosciences (XBIO) Net Cash Flow (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Net Cash Flow data on file, last reported at -$536377.0 in Q1 2026.
- Quarterly Net Cash Flow rose 46.46% year-over-year to -$536377.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (up 31.54% YoY) and the FY2025 annual result came in at $1.7 million, up 160.98% from the prior year.
- Net Cash Flow slipped to -$536377.0 in Q1 2026, from -$242682.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of -$242682.0 in Q4 2025 to a low of -$2.1 million in Q1 2022.
- A 5-year average of -$847146.5 and a median of -$750907.0 in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 74.11% — and 2025, when it jumped 63.99%.
- Tracing XBIO's Net Cash Flow over 5 years: stood at -$750907.0 in 2022, then decreased by 5.61% to -$793027.0 in 2023, then increased by 15.01% to -$673992.0 in 2024, then jumped by 63.99% to -$242682.0 in 2025, then plunged by 121.02% to -$536377.0 in 2026.
- The last three Net Cash Flow figures came in at -$536377.0 (Q1 2026), -$242682.0 (Q4 2025), and -$658247.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | -875,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -875,489.00 |
| Jun 30, 2026 | -875,489.00 |
| Mar 31, 2026 | -536,377.00 |
| Mar 31, 2026 | -536,377.00 |
| Dec 31, 2025 | -242,682.00 |
| Dec 31, 2025 | -242,682.00 |
| Sep 30, 2025 | -658,247.00 |
| Sep 30, 2025 | -658,247.00 |
| Jun 30, 2025 | -383,830.00 |
| Jun 30, 2025 | -383,830.00 |
| Mar 31, 2025 | -1.00 Mn |
| Mar 31, 2025 | -1.00 Mn |
| Dec 31, 2024 | -673,992.00 |
| Dec 31, 2024 | -673,992.00 |
| Sep 30, 2024 | -459,037.00 |
| Sep 30, 2024 | -459,037.00 |
| Jun 30, 2024 | -525,104.00 |
| Jun 30, 2024 | -525,104.00 |
| Mar 31, 2024 | -1.16 Mn |
| Mar 31, 2024 | -1.16 Mn |